Particular emphasis is devoted in the US to identify the determinants of, and eventually remedies, for the disproportionate share of the cancer burden borne by underrepresented minorities. Incidence rates for many forms of cancer are higher among blacks than whites. The disparity is compounded by lower rates of relative survival for almost all cancers, so that age-adjusted mortality rates are substantially higher among African Americans than whites for about two-thirds of all types of cancers. Our Cancer Partnership provides an exceptional environment to focus the efforts of diverse investigators working across many disciplines to address health disparities in NCI designated cancer centers and to develop research infrastructure, capacity and effectiveness of minority-serving institutions. Collectively, these efforts offer the best opportunity to overcome cancer disparities and optimize research resources and infrastructure. Our Partnership has matured and developed strong, successful collaborative interactions based on excellence, true reciprocity and mutual benefit to achieve this goal. Moreover, this Partnership is geographically placed in a region with the highest cancer incidence in the US, pointing to the enormous potential for improved outcomes through the proposed work. We are dedicated to enhancing the strengths and eliminating the weaknesses of our three institutions as we move toward our shared goal of eliminating cancer disparities. The overall objectives of this competing renewal application are to: (1) increase and stabilize the competitive cancer research capability of Meharry Medical College (MMC) and Tennessee State University (TSU); (2) create stable, long-term collaborative relationships between MMC, TSU and the Vanderbilt Ingram Cancer Center (VICC) in cancer research, research education, career development and cancer outreach; (3) expand access to clinical trials for minority populations served by Nashville General Hospital (NGH)/MMC, and (4) improve the effectiveness of VICC research, career development, education and outreach activities specifically designed to benefit minority populations served by VICC. All activities will be monitored by an Internal Advisory Committee and the Program Steering Committee with representation from the NCI. A sustained and comprehensive Cancer Partnership is of immense benefit to the three participating institutions as well as the mid-South region of the US. The common mission statement for our Cancer Partnership is to conduct rigorous basic, translational and clinical research directed towards the reduction of disparities in the incidence and treatment of cancer through a multidisciplinary collaborative approach to research, education and community engagement. As a triad we will amplify cancer research capabilities in the greater Nashville academic and healthcare community, improve and document outcomes in the diagnosis and treatment of cancer in minority and underserved communities, minimize or eliminate measurable disparities in the incidence of cancer among minority populations, and fortify collaborations among the three partner organizations.

Public Health Relevance

Our Cancer Partnership provides an exceptional environment to identify the determinants and address the disproportionate share of the cancer burden borne by underrepresented minorities, as evidenced by higher incidence rates and lower rates of relative survival. The conduct of minority-targeted cancer research, development of research infrastructure, enhancement of minority education programs and improvement to the capacity/effectiveness of cancer-related activities will address these health disparities in the greater Nashville academic and healthcare community with the ultimate goal to improve outcomes in the diagnosis and treatment of cancer in minority and underserved communities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163069-09
Application #
9765041
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Wali, Anil
Project Start
2011-09-26
Project End
2021-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Meharry Medical College
Department
Biochemistry
Type
Schools of Medicine
DUNS #
041438185
City
Nashville
State
TN
Country
United States
Zip Code
37208
Umeukeje, Ebele M; Wild, Marcus G; Maripuri, Saugar et al. (2018) Black Americans' Perspectives of Barriers and Facilitators of Community Screening for Kidney Disease. Clin J Am Soc Nephrol 13:551-559
Vercruysse, Koen; Clark, Astiney; Alatas, Noor et al. (2018) Polysaccharide-mediated synthesis of melanins from serotonin and other 5-hydroxy indoles. Future Sci OA 4:FSO280
Hull, P C; Buchowski, M; Canedo, J R et al. (2018) Childhood obesity prevention cluster randomized trial for Hispanic families: outcomes of the healthy families study. Pediatr Obes 13:686-696
Sanderson, Maureen; Aldrich, Melinda C; Levine, Robert S et al. (2018) Neighbourhood deprivation and lung cancer risk: a nested case-control study in the USA. BMJ Open 8:e021059
Ochieng, Josiah; Nangami, Gladys; Sakwe, Amos et al. (2018) Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. Int J Mol Sci 19:
Tantawy, Mohammed N; Charles Manning, H; Peterson, Todd E et al. (2018) Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model. Mol Imaging Biol 20:200-204
Burroughs, Andrea Flores; Eluhu, Sylvia; Whalen, Diva et al. (2018) PML-Nuclear Bodies Regulate the Stability of the Fusion Protein Dendra2-Nrf2 in the Nucleus. Cell Physiol Biochem 47:800-816
Ignacio, Rosa Mistica C; Lee, Eun-Sook; Wilson, Andrew J et al. (2018) Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer. Immune Netw 18:e29
Wilkins, Consuelo H (2018) Putting The Person In Personalized Medicine Personalized Medicine: Empowered Patients In The 21st Century? By Barbara Prainsack New York (NY) : NYU Press , 2017 288 pp., $30. Health Aff (Millwood) 37:823-824
Ignacio, Rosa Mistica C; Dong, Yuan-Lin; Kabir, Syeda M et al. (2018) CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer. Oncotarget 9:9751-9765

Showing the most recent 10 out of 178 publications